Get the Stockscreener App
5.61
8.63%
-0.53
After Hours:
5.83
0.22
+3.92%
Solid Biosciences Inc stock is traded at $5.61, with a volume of 1.14M.
It is down -8.63% in the last 24 hours and down -9.95% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$6.14
Open:
$5.94
24h Volume:
1.14M
Relative Volume:
1.11
Market Cap:
$437.08M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.8454
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
-10.81%
1M Performance:
-9.95%
6M Performance:
+2.00%
1Y Performance:
-2.60%
1-Day Range:
$5.5239
$5.99
1-Week Range:
$5.5239
$6.55
52-Week Range:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.61 | 478.37M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Needham | Buy |
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Solid Biosciences (SLDB) Stock Price, News & Analysis - MarketBeat
Biotech Sector Sustains After-Hours Trading Gains - Intellectia AI
Solid Biosciences (SLDB) Projected to Post Earnings on Thursday - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Inc. sponsors international muscular dystrophy conference in Rome - Traders Union
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Solid Biosciences CTO Herzich sells $21k in shares By Investing.com - Investing.com South Africa
Solid Biosciences CEO Cumbo sells $96k in shares By Investing.com - Investing.com Canada
Solid Biosciences CTO Herzich sells $21k in shares - Investing.com India
Patterns Watch: What are Solid Biosciences Incs earnings expectationsMarket Activity Recap & Safe Entry Trade Signal Reports - baoquankhu1.vn
David Howton Sells 7,469 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells $96,868.08 in Stock - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Insider Jessie Hanrahan Sells 4,134 Shares - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) Director Sells 2,658 Shares of Stock - MarketBeat
Solid Biosciences CFO Tan sells $31k in shares - Investing.com Nigeria
Solid Biosciences CFO Tan sells $31k in shares By Investing.com - Investing.com Nigeria
Solid Biosciences COO Howton sells $43k in shares By Investing.com - Investing.com Nigeria
Solid Biosciences director’s wife sells $15k in shares By Investing.com - Investing.com Canada
Solid Biosciences chief regulatory officer Hanrahan sells $24k in SLDB stock - Investing.com Australia
Solid Biosciences COO Howton sells $43k in shares - Investing.com
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 5,404 Shares - MarketBeat
Insider sale notice at Solid Biosciences (NASDAQ: SLDB) for RSU settlement - Stock Titan
Harahan Jessie files Form 144 to sell 4,134 SLDB shares (SLDB) - Stock Titan
Solid Biosciences supports Jett Foundation RareDiseaseDay event - Traders Union
Solid Biosciences Insiders Sold US$823k Of Shares Suggesting Hesitancy - simplywall.st
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update - MarketBeat
Why is Solid Biosciences Inc. stock going upJuly 2025 Trends & Risk Managed Trade Strategies - mfd.ru
SLDB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
What analysts say about Solid Biosciences Inc. stockQuarterly Investment Review & Growth-Oriented Investment Plans - mfd.ru
Solid Biosciences (SLDB) Gets a Buy from Wedbush - The Globe and Mail
Adage discloses 1.8% Solid Biosciences (SLDB) ownership stake - Stock Titan
Citizens reiterates Market Outperform rating on Solid Biosciences stock - Investing.com Nigeria
Citizens reiterates Market Outperform rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Solid Biosciences advances Duchenne treatment with FDA alignment By Investing.com - Investing.com Australia
Solid Biosciences advances Duchenne treatment with FDA alignment - Investing.com South Africa
Solid Biosciences: Positive FDA Meeting SGT-003 Sets Up Next Milestones (NASDAQ:SLDB) - Seeking Alpha
Needham Reiterates Buy Rating for Solid Biosciences (SLDB) at $1 - GuruFocus
Needham & Company LLC Reaffirms Buy Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (SLDB) Gains FDA Alignment for Duchenne Trial - GuruFocus
Solid Biosciences Receives Positive FDA Feedback - Intellectia AI
Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26 - Nasdaq
Solid Biosciences stock rises after FDA alignment on Phase 3 trial design - Investing.com Nigeria
Solid Biosciences (SLDB) Advances Duchenne Therapy with FDA Supp - GuruFocus
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):